PMID- 31475560
OWN - NLM
STAT- MEDLINE
DCOM- 20200422
LR  - 20200422
IS  - 1802-9973 (Electronic)
IS  - 0862-8408 (Print)
IS  - 0862-8408 (Linking)
VI  - 68
IP  - 5
DP  - 2019 Oct 25
TI  - Epoxyeicosanoids in hypertension.
PG  - 695-704
AB  - Epoxyeicosatrienoic acids (EETs) are also known as epoxyeicosanoids that have 
      renal and cardiovascular actions. These renal and cardiovascular actions can be 
      regulated by soluble epoxide hydrolase (sEH) that degrades and inactivates EETs. 
      Extensive animal hypertension studies have determined that vascular, epithelial 
      transport, and anti-inflammatory actions of EETs lower blood pressure and 
      decrease renal and cardiovascular disease progression. Human studies have also 
      supported the notion that increasing EET levels in hypertension could be 
      beneficial. Pharmacological and genetic approaches to increase epoxyeicosanoids 
      in several animal models and humans have found improved endothelial vascular 
      function, increased sodium excretion, and decreased inflammation to oppose 
      hypertension and associated renal and cardiovascular complications. These 
      compelling outcomes support the concept that increasing epoxyeicosanoids via sEH 
      inhibitors or EET analogs could be a valuable hypertension treatment.
FAU - Imig, J D
AU  - Imig JD
AD  - Department of Pharmacology and Toxicology, Cardiovascular Center, Medical College 
      of Wisconsin, Milwaukee, WI, USA. jdimig@mcw.edu.
LA  - eng
GR  - R01 DK103616/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20190902
PL  - Czech Republic
TA  - Physiol Res
JT  - Physiological research
JID - 9112413
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Eicosanoids)
RN  - 0 (Enzyme Inhibitors)
RN  - EC 3.3.2.- (Epoxide Hydrolases)
SB  - IM
MH  - Animals
MH  - Antihypertensive Agents/*therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Eicosanoids/metabolism/*therapeutic use
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Epoxide Hydrolases/*antagonists & inhibitors/metabolism
MH  - Humans
MH  - Hypertension/*drug therapy/metabolism/physiopathology
MH  - Signal Transduction
PMC - PMC6941753
MID - NIHMS1064949
COIS- Conflict of Interest Dr. Imig has patents that cover the composition of matter 
      for EET analogs. There are no other conflicts of interest, financial or 
      otherwise, are declared by the author.
EDAT- 2019/09/03 06:00
MHDA- 2020/04/23 06:00
PMCR- 2020/01/03
CRDT- 2019/09/03 06:00
PHST- 2019/09/03 06:00 [pubmed]
PHST- 2020/04/23 06:00 [medline]
PHST- 2019/09/03 06:00 [entrez]
PHST- 2020/01/03 00:00 [pmc-release]
AID - 934291 [pii]
AID - 10.33549/physiolres.934291 [doi]
PST - ppublish
SO  - Physiol Res. 2019 Oct 25;68(5):695-704. doi: 10.33549/physiolres.934291. Epub 
      2019 Sep 2.